| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
*
Department of Microbiology, University of Tennessee, Knoxville, TN 37996; and
Department of Microbiology, Faculty of Pharmacy, Tanta University, Tanta, Egypt
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Currently, the prime-boost strategy has been investigated in situations where both priming and boosting immunizations were administered systemically (4, 5, 6, 7). Moreover, measurements of efficacy focused on components of systemic immunity (4, 5, 6, 7). Because for many pathogens the portal of entry is by way of mucosal surfaces, and immunity at such sites can limit or even preclude infection (8), it is also important to evaluate prime-boost strategies for their effects on mucosal defense. In the present report we have compared the efficacies of the prime-boost approach using a DNA vaccine encoding glycoprotein gB of herpes simplex virus (gB DNA)3 and that using a recombinant vaccinia virus vaccine encoding gB (rvacgB) given mucosally as well as systemically for their effects on systemic and mucosal immunity. Our results confirm that systemic priming with gB DNA followed by boosting with rvacgB resulted in superior systemic humoral and T cell-mediated immunity. However, this approach failed to induce detectable immunity at mucosal sites. In contrast, mucosal priming with gB DNA and mucosal boosting with rvacgB induced excellent mucosal immune responses and also caused enhanced systemic immunity. Of particular interest, maximal mucosal immunity was achieved if rvacgB was used to mucosally prime animals and gB DNA was used as a mucosal booster. Thus, our results demonstrate that the prime-boost strategy may result in excellent mucosal immunity, but the order of immunization should be to prime mucosally with recombinant viral vector and to use DNA vaccines given mucosally to boost responses.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Female 4- to 5-wk-old BALB/c (H-2d) and C57BL/6 (H-2b) mice were purchased from Harlan Sprague Dawley (Indianapolis, IN) and housed in the animal facilities at the University of Tennessee. HSV-1 KOS and McKrae strains were grown in Vero cells obtained from American Type Culture Collection (Manassas, VA), whereas rvacgB and vaccinia virus tk- (vvtk-) were grown in CV-1 cells (American Type Culture Collection). The viruses were concentrated, titrated, and stored in aliquots at -80°C until use.
Preparation of plasmid DNA vaccine
Plasmid DNA encoding gB (gB DNA) under the CMV promoter has been described in detail previously (9). The plasmid DNA was purified as previously described (10).
Immunization and sample collection
Groups of mice (3- to 4-wk-old female mice) were immunized with either 100 µg of gB DNA or 107 PFU of rvacgB via the intranasal (i.n.) or the intramuscular (i.m.) route and then boosted 10 days later with alternative vaccine vehicle via the same or a different route. Serum samples from mice were collected by retro-orbital bleeding. Vaginal lavages were obtained by introduction of 100 µl of PBS (pH 7.2) into the vaginal canals, followed by recovery with micropipette.
ELISA for gB-specific Abs
The gB-specific Abs in the samples were determined by standard ELISA as described previously (11). Briefly, ELISA plates were coated with gB protein (provided by Chiron, Emeryville, CA) and goat anti-mouse IgG (Southern Biotechnology Associates, Birmingham, AL) or rabbit anti-mouse IgA (Zymed, San Francisco, CA), then incubated overnight at 4°C. The plates were washed with PBST (PBS containing Tween 20; three times) and blocked with a 3% solution of dehydrated milk. Samples were 2-fold serially diluted, incubated for 2 h at 37°C, and then incubated with goat anti-mouse IgG-conjugated HRP (IgG-HRP) for 1 h. For measurement of IgA levels in vaginal lavage, biotinylated goat anti-mouse IgA was first added for 2 h at 37°C, followed by peroxidase-conjugated streptavidin (Jackson ImmunoResearch, West Grove. PA). After color development, Ab concentrations were calculated with an automated ELISA reader (Spectra MAX340; Molecular Devices, Sunnyvale, CA).
Quantification of IFN-
-producing CD4+ Th cells
The enzyme-linked immunospot (ELISPOT) assay was used for
quantification of cytokine-producing cells as described previously
(10). Briefly, ELISPOT plates (Millipore, Molseheim,
France) were previously coated with IFN- anti-mouse Ab. The
immune T cells (responder cells) were mixed with syngeneic splenocytes
(stimulator cells) pulsed with UV-inactivated HSV (multiplicity of
infection, 5.0 before UV inactivation). Coincubation of the responder
and stimulator cells was continued for 72 h at 37°C. The ELISPOT
plates were washed three times with PBS and three times with PBST, then
biotinylated IFN- Ab was added to the plates for 1 h at 37°C.
The spots were developed using nitro blue tetrazolium (Sigma, St.
Louis, MO) and 5-bromo-4-chloro-3-indolylphosphate (Sigma) as a
substrate following incubation with alkaline phosphatase-conjugated
streptavidin (Jackson ImmunoResearch) for 1 h and counted 24
h later under a stereomicroscope.
CTL assay
CTL activity was accessed by a standard 5-h 51Cr release assay against labeled target cells as previously described (12). Splenocytes and corresponding draining lymph node (DLN) lymphocytes (effector cells) were restimulated in vitro with syngeneic splenocytes pulsed with gB498–505 (SSIEFARL) peptide specific for MHC class I (H-2b)-restricted CD8+ T lymphocytes at a concentration of 10 µg/ml for 5 days. The effector cells were then mixed at various ratios with 51Cr-labeled target cells for 5 h. The target cells included MHC-matched EL-4 (H-2b) and MHC-mismatched EMT-6 (H-2d) pulsed with SSIEFARL peptide. Spontaneous release of 51Cr was determined by incubating the target cells with medium alone, and maximum release was determined by adding Triton X-100 to a final concentration of 5%. To calculate the specific lysis of targets, the percent lysis of irrelevant targets was subtracted from the percent lysis of specific targets. The percent specific lysis was calculated as follows: 100 x ([experimental release - spontaneous release]/[maximum release - spontaneous release]). Each experiment was performed twice, using triplicate samples.
Preparation of vaginal and iliac lymph node (LN) cells
Vaginal T lymphocytes were prepared as previously described (13, 14) with some modification. Briefly, vaginas were excised, cut longitudinally, and minced with a sterile scalpel in HBSS without calcium and magnesium (Life Technologies, Gaithersburg, MD). After washes with HBSS containing 1 mM EDTA (four time), minced tissues were digested in RPMI medium containing 1 mg of collagenase type VIII (Sigma)/ml and 1 mg of dispase II (Roche, Indianapolis, IN)/ml. Digestion was performed under stirring (1 h, 37°C). Cells were filtered through a sterile gauze mesh and washed with RPMI medium. Additional tissue debris was excluded by low speed centrifugation (200 x g, 10 min). Cells were collected by an additional centrifugation (400 x g, 10 min), resuspended in RPMI medium, and enriched on a nylon-wool column. Vaginal cells for Ab-producing cells were used before application to the nylon-wool column. Approximately 2–3x106 cells were collected from seven mice. After eluting vaginal cells through the nylon-wool column, the vaginal cells usually showed 40–60% CD4+ T cells by flow cytometric analysis. Iliac LN cells were isolated from excised iliac LN, and then contaminating erythrocytes were lysed by hypotonic shock with a 0.83% ammonium chloride solution.
ELISPOT for Ab-producing cells
The numbers of gB-specific IgG and IgA-producing cells in iliac LN and vaginal tract were determined by ELISPOT assay as described previously (10). Briefly, ELISPOT plates (Millipore) were coated with 200–400 ng of gB protein/well and incubated overnight at 4°C. For determination of the total number of IgG and IgA spot-forming cells, the plates were coated with 200 ng of rabbit anti-mouse IgG or IgA (Zymed)/well. After blocking with RPMI medium with 10% FBS, the cells were loaded in 100-µl volumes and incubated for 72 h at 37°C. The plates were then washed three times with PBS and subsequently with PBST, then incubated with biotinylated goat anti-mouse IgG or IgA (Zymed) for 1 h at 37°C. The spots were developed with nitro blue tetrazolium and 5-bromo-4-chloro-3-indolylphosphate substrates after incubation with alkaline phosphatase-streptavidin conjugate for 1 h and counted 24 h later under a stereomicroscope.
Statistical analysis
Significant differences between groups were evaluated using Student’s t test.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
To compare the effectiveness of systemic and mucosal immune
induction following systemic or mucosal immunization using a
prime-boost regimen, groups of BALB/c mice were primed mucosally (i.n.)
or systemically (i.m.) with gB DNA or rvacgB and boosted 10 days later
via the same route used for priming with the alternative vector. Some
mice were immunized with vector DNA or vvtk- to
act as negative controls. Ten days following boosting, levels of
systemic and mucosal immunity were evaluated by determining serum
gB-specific IgG and vaginal gB-specific IgA responses. Firstly,
confirming results in other systems (3, 6, 7), priming
systemically with gB DNA and boosting systemically with rvacgB led to
excellent serum IgG levels (Fig. 1
A). These exceeded those
achieved by priming and boosting with the same vaccine and were also
superior to responses induced by systemic priming with rvacgB and
systemic boosting with gB DNA. However, none of the systemic
prime-boost approaches induced detectable gB-specific vaginal IgA
responses (Fig. 1B).
|
B). Of particular interest, the maximal gB-specific IgA
responses were induced if animals received rvacgB mucosally as the
priming vaccine, followed by mucosal boosting with gB DNA (Fig. 1B). Moreover, such a protocol provided significantly higher
serum IgG levels than did gB DNA systemic priming-rvacgB systemic
boosting (p < 0.05; Fig. 1A). It is
worth noting that vaginal IgA as well as serum IgG responses were
higher in mice that received rvacgB priming-gB DNA boosting than in
mice primed and boosted mucosally with the same vaccine type.
To further evaluate the efficacy of the different prime-boost
approaches, mice immunized as described above were challenged vaginally
with a virulent strain of HSV-1 8 wk after boosting and were killed 4
days later to measure mucosal immunity by a more quantitative assay.
Accordingly, the ELISPOT approach was used to measure the frequency of
gB-specific IgA- and IgG-producing cells in the vaginal tract and iliac
LN (ILN). Once again, it was evident that the rvacgB mucosally prime-gB
DNA mucosally boost protocol induced the highest frequency of
gB-specific IgA and IgG producers in both ILN and the vaginal tract
(Table I). With regard to systemic
immunization, gB DNA systemic priming-rvacgB systemic boosting provided
detectable, but markedly fewer, numbers of gB-specific Ab-producing
cells than was attained by mucosal immunization (Table I). These
results further demonstrate that maximal mucosal humoral immunity
resulted from administration of the priming-boost regimen via the
mucosal route, and maximal immunity occurred if rvacgB was used for the
priming step.
|
BALB/c mice immunized in various ways to measure systemic and
mucosal T cell-mediated immunity were killed on the 15th day
postboosting. Spleen and DLN were collected to enumerate numbers of
IFN--producing cells following stimulation with UV-inactivated HSV.
This assay is considered primarily as a measurement of
CD4+ T cell function (9). In other
experiments C57BL/6 mice were immunized by the various protocols,
because only in this mouse strain does gB have a strong MHC class I
(H-2b)-restricted epitope (SSIEFARL), making measurement of
CD8+ T cell responses more precise (15, 16).
As evident in Fig. 2, when both priming
and boosting vaccines were given systemically, optimal
IFN--producing CD4+ T cells responses occurred
in spleens of gB DNA-primed/rvacgB-boosted mice. However, in those mice
immunized mucosally, maximal CD4+ T cell-mediated
responses were evident in mice primed with rvacgB and boosted with gB
DNA (Fig. 2). This pattern of IFN--producing
CD4+ T cell responses was also seen when DLN
cells were quantified for IFN- spot-forming cells (Fig. 2). We also
analyzed the frequency of IFN--producing cells in ILN and vaginal
tract of mice infected vaginally 4 days before killing with a virulent
strain of HSV-1. Once again, mice primed mucosally with rvacgB and gB
DNA boosted generated higher frequencies of IFN--producing cells
than occurred with other protocols (Table I).
|
). Most notably, immunization via the
mucosal route generated optimal responses when rvacgB was used to prime
and gB DNA was used as the boosting vaccine. Mucosal
CD8+ T cell responses were also detectable in the
LN draining the immunization site as well as distally in the mesenteric
LN (Fig. 3, B and D). Whereas mucosal
immunization generated responses in the mesenteric LN, all systemic
immunization failed to cause such responses.
|
The above results with prime-boost immunization indicate that
optimal mucosal humoral and T cell-mediated responses required that the
vaccines should be administered mucosally. To determine whether mucosal
administration at both the priming and boosting steps was critically
important, immune responses were compared in mice primed and boosted by
the same route with those primed by one route and boosted by the other.
The results summarized in Fig. 4 show
systemic and mucosal humoral responses as well as IFN--producing
CD4+ T cell responses in the various groups. It
is evident that the maximal responses occurred if both priming and
boosting were administered mucosally. However, mucosal priming appeared
to be more important than mucosal boosting, because mice that received
mucosal priming and systemic boosting had higher levels of mucosal
immunity than those systemically primed and mucosally boosted (Fig. 4, A and B). These effects were most evident with
gB-specific vaginal IgA responses (Fig. 4B), but were also
noted with both IFN--producing CD4+ T cells
(Fig. 4C) and CD8+ T cell-mediated CTL
responses (data not shown). Thus, these results indicate that mucosal
administration at the priming step is critical for inducing maximal
mucosal immunity in prime-boost approaches.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The discovery that plasmid DNA encoding viral proteins could be immunogenic initiated the idea of using DNA as a practical means of vaccination (1). Although this objective has yet to be met, recent observations that DNA vaccines given as the first step of a prime-boost protocol induced effective immunity have moved DNA vaccines closer to practical reality (3, 4, 5, 6, 7, 17). Such prime-boost protocols induce excellent levels of humoral as well as T cell immunity, emphasizing CD8+ and type 1 CD4+ T cell responses important for defense against intracellular pathogens (6, 7, 18, 19). It is still not clear why the DNA prime-viral vector boost approach induces superior immunity or if the system can be even further improved by adding other components, such as cytokines and adjuvants.
Previous reports using prime-boost strategies administered vaccines parenterally and looked only at systemic immunity (3, 4, 5, 6, 7, 17, 18, 19). However, for many pathogens immunity at mucosal surfaces represents a critical determinant of immune defense (8). Moreover, many vaccines, while inducing excellent systemic immunity, may be inferior inducers of mucosal protection (1, 20, 21). As shown in this report, with i.m. administered gB DNA and rvacgB, excellent systemic humoral and T cell responses were induced, but mucosal responses were undetectable. However, mucosal Ab and T cell-mediated responses occurred if the vaccines were administered mucosally. As is often the case with mucosal immunization, immunity was evident at mucosal sites distal from the site of immunization, indicating the operation of an interlinked mucosal immune system (22, 23, 24, 25). In addition, prime-boost vaccination by the mucosal route induced notable systemic immune responses. This was not surprising, because after mucosal administration of DNA vaccine, plasmid DNA is known to gain access to multiple organs, including central lymphoid tissues (26). In addition, as we have shown previously, i.n. administration of rvacgB not only induces excellent vaginal and intestinal immunity, but also elicits systemic humoral and T cell-mediated immunity (24). Accordingly, the prime-boost formulation given mucosally represents a valuable means of inducing mucosal as well as systemic immunity and should be valuable in situations when both types of immune induction represent the objective.
Unexpectedly, when using the prime-boost approach mucosally, the vaccine sequence that provided optimal results was the reverse of that which works best following systemic administration. Accordingly, rvacgB priming followed by DNA gB boosting achieved maximal responses both mucosally and systemically. Furthermore, when protocols were used in which mucosal and systemic routes were heterogeneous, priming mucosally was shown to be the critical event. Reasons why rvacgB priming via the mucosal route proved superior to gB DNA priming remains to be defined. One explanation could lie with the potency of the primary immunogen combined with possible interference by pre-existing immunity with boost immunizations. Thus, as we have shown previously (24), i.n. rvacgB immunization represents a more potent means of inducing a vaginal IgA response than does gB DNA immunization. The potency gap could be narrowed by incorporating an adjuvant such as cholera toxin B (CTB) along with DNA vaccine for i.n. administration (10). We have also found that gB DNA priming along with CTB followed by rvacgB boosting induces better mucosal immune responses than does gB DNA priming without CTB (data not shown). A second aspect of the explanation could lie with interference by pre-existing immunity. Thus, for example, DNA vaccines appear unaffected by pre-existing immunity (27, 28). This makes then potentially valuable vaccines in animals, such as newborns that possess high levels of passive immunity (28, 29). In contrast, immune responses to attenuated vaccines can be limited by pre-existing immunity (27, 28, 29), although in the case of recombinant vaccinia virus vectors this effect may be less when vaccines are administered mucosally (25). We are currently assessing the role of interfering humoral immunity resulting from priming using B cell-deficient (µK/O) animals unable to generate Ab responses.
In conclusion, our observations demonstrate that immunization via the mucosal route with a recombinant viral vector vaccine followed by boosting with a DNA vaccine represents an effective means of inducing both mucosal and systemic humoral and T cell-mediated immunities. In contrast to systemic protocols when used mucosally, the prime-boost immunization approach works most effectively if DNA vaccine is used to boost, rather than prime, immunity.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Barry T. Rouse, Department of Microbiology, M409 Walters Life Sciences Building, University of Tennessee, Knoxville, TN 37996-0845.
3 Abbreviations used in this paper: gB DNA, DNA vaccine encoding glycoprotein gB of herpes simplex virus; rvacgB, recombinant vaccinia virus vaccine encoding gB; i.n., intranasal(ly); ELISPOT, enzyme-linked immunospot; LN, lymph node; DLN, draining LN; ILN, iliac LN; CTB, cholera toxin B; i.m., intramuscular(ly).
Received for publication February 2, 2001. Accepted for publication February 23, 2001.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This article has been cited by other articles:
|
|
 |
|
  A. E. Snook, B. J. Stafford, P. Li, G. Tan, L. Huang, R. Birbe, S. Schulz, M. J. Schnell, M. Thakur, J. L. Rothstein, et al. Guanylyl Cyclase C-Induced Immunotherapeutic Responses Opposing Tumor Metastases Without Autoimmunity J Natl Cancer Inst, July 2, 2008; 100(13): 950 - 961. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Gherardi and M. Esteban Recombinant poxviruses as mucosal vaccine vectors J. Gen. Virol., November 1, 2005; 86(11): 2925 - 2936. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. N. Toka, S. Suvas, and B. T. Rouse CD4+ CD25+ T Cells Regulate Vaccine-Generated Primary and Memory CD8+ T-Cell Responses against Herpes Simplex Virus Type 1 J. Virol., December 1, 2004; 78(23): 13082 - 13089. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Peacock, S. K. Nordone, S. S. Jackson, H.-X. Liao, N. L. Letvin, A. G. Yafal, L. Gritz, G. P. Mazzara, B. F. Haynes, and H. F. Staats Gender Differences in Human Immunodeficiency Virus Type 1-Specific CD8 Responses in the Reproductive Tract and Colon following Nasal Peptide Priming and Modified Vaccinia Virus Ankara Boosting J. Virol., December 1, 2004; 78(23): 13163 - 13172. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Devito, B. Zuber, U. Schroder, R. Benthin, K. Okuda, K. Broliden, B. Wahren, and J. Hinkula Intranasal HIV-1-gp160-DNA/gp41 Peptide Prime-Boost Immunization Regimen in Mice Results in Long-Term HIV-1 Neutralizing Humoral Mucosal and Systemic Immunity J. Immunol., December 1, 2004; 173(11): 7078 - 7089. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. O. Lasaro, W. B. Luiz, M. E. Sbrogio-Almeida, L. S. Nishimura, B. E. C. Guth, and L. C. S. Ferreira Combined Vaccine Regimen Based on Parenteral Priming with a DNA Vaccine and Administration of an Oral Booster Consisting of a Recombinant Salmonella enterica Serovar Typhimurium Vaccine Strain for Immunization against Infection with Human-Derived Enterotoxigenic Escherichia coli Strains Infect. Immun., November 1, 2004; 72(11): 6480 - 6491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Gherardi, E. Perez-Jimenez, J. L. Najera, and M. Esteban Induction of HIV Immunity in the Genital Tract After Intranasal Delivery of a MVA Vector: Enhanced Immunogenicity After DNA Prime-Modified Vaccinia Virus Ankara Boost Immunization Schedule J. Immunol., May 15, 2004; 172(10): 6209 - 6220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Garulli, Y. Kawaoka, and M. R. Castrucci Mucosal and Systemic Immune Responses to a Human Immunodeficiency Virus Type 1 Epitope Induced upon Vaginal Infection with a Recombinant Influenza A Virus J. Virol., January 15, 2004; 78(2): 1020 - 1025. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. N. Toka, M. Gierynska, and B. T. Rouse Codelivery of CCR7 Ligands as Molecular Adjuvants Enhances the Protective Immune Response against Herpes Simplex Virus Type 1 J. Virol., December 1, 2003; 77(23): 12742 - 12752. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Lemiale, W.-p. Kong, L. M. Akyurek, X. Ling, Y. Huang, B. K. Chakrabarti, M. Eckhaus, and G. J. Nabel Enhanced Mucosal Immunoglobulin A Response of Intranasal Adenoviral Vector Human Immunodeficiency Virus Vaccine and Localization in the Central Nervous System J. Virol., September 15, 2003; 77(18): 10078 - 10087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. P. Goonetilleke, H. McShane, C. M. Hannan, R. J. Anderson, R. H. Brookes, and A. V. S. Hill Enhanced Immunogenicity and Protective Efficacy Against Mycobacterium tuberculosis of Bacille Calmette-Guerin Vaccine Using Mucosal Administration and Boosting with a Recombinant Modified Vaccinia Virus Ankara J. Immunol., August 1, 2003; 171(3): 1602 - 1609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. T. Evans, L.-M. Chen, J. Gillis, K.-C. Lin, B. Harty, G. P. Mazzara, R. O. Donis, K. G. Mansfield, J. D. Lifson, R. C. Desrosiers, et al. Mucosal Priming of Simian Immunodeficiency Virus-Specific Cytotoxic T-Lymphocyte Responses in Rhesus Macaques by the Salmonella Type III Secretion Antigen Delivery System J. Virol., February 15, 2003; 77(4): 2400 - 2409. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Koelle and L. Corey Recent Progress in Herpes Simplex Virus Immunobiology and Vaccine Research Clin. Microbiol. Rev., January 1, 2003; 16(1): 96 - 113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Morello, M. Ye, and D. H. Spector Development of a Vaccine against Murine Cytomegalovirus (MCMV), Consisting of Plasmid DNA and Formalin-Inactivated MCMV, That Provides Long-Term, Complete Protection against Viral Replication J. Virol., April 16, 2002; 76(10): 4822 - 4835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. U. Vogel, B. E. Beer, J. zur Megede, H.-G. Ihlenfeldt, G. Jung, S. Holzammer, D. I. Watkins, J. D. Altman, R. Kurth, and S. Norley Induction of anti-simian immunodeficiency virus cellular and humoral immune responses in rhesus macaques by peptide immunogens: correlation of CTL activity and reduction of cell-associated but not plasma virus load following challenge J. Gen. Virol., January 1, 2002; 83(1): 81 - 91. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
